Hypertension Trial, Recruiting NCT05475015 Sponsor: Shengjing Hospital Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT05475015
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who are willing and able to provide written consent to participate
  • People who have been diagnosed with advanced chronic liver disease (long-term scarring of the liver), caused by any underlying condition
  • People for whom a liver pressure measurement procedure (called HVPG) has been recommended by their doctor, and who have already had a specific type of MRI scan (called 3D-MRE) within the past month

Who may not be able to join:

  • People who have cancer in the liver or elsewhere in the body, or large growths in the liver or spleen that could affect the MRI scan results
  • People who have a medical reason why they cannot safely have an MRI scan or the liver pressure measurement procedure
  • People who have previously had surgery on their liver or spleen that could affect the MRI scan results
  • People who have taken a type of blood pressure medication called non-selective beta-blockers in the period between their MRI scan and their liver pressure measurement
  • People whose MRI scan or liver pressure measurement results were not clear or reliable enough to use
  • People who have a blockage or widening of the bile ducts visible on their MRI scan

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yu Shi, Prof., Shengjing Hospital

Phone: +86 158 0000 4518

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
16 August 2022
Est. completion
1 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Accuracy of the features of 3D-MRE for assessing portal hypertension in cirrhosis.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov